Zambon Biotech

Zambon Biotech is the specialized business unit of the international pharmaceutical group Zambon, dedicated to the development and commercialization of innovative therapies for rare and specialty diseases. The company focuses primarily on severe respiratory conditions, such as Bronchiolitis Obliterans Syndrome (BOS) and cystic fibrosis, as well as central nervous system disorders like Parkinson's disease. Zambon Biotech operates with a lean, agile model, leveraging a global network of partners to advance its late-stage clinical pipeline. Its portfolio includes liposomal cyclosporine A for lung transplant complications and advanced inhaled antibiotics for chronic lung infections. The company is headquartered in Switzerland and utilizes the OpenZone scientific campus in Italy for research and development activities. By focusing on high-unmet-need areas, Zambon Biotech aims to transform the lives of patients with life-threatening conditions through precision medicine and advanced delivery technologies.